Introduction {#sec1_1}
============

Neuroendocrine tumors (NETs) constitute a heterogeneous group of neoplasia, gathered together because of their common features: tumors capable of secreting hormones, neurotransmitters, neuromodulators and neuropeptides. Neuroendocrine cells, supposedly precursors of this group of neoplasia, are found in all solid organs, skin and mucosae; therefore, NETs may originate in several locations \[[@B1], [@B2], [@B3]\].

Their incidence varies in different studies. Data from the US and Europe indicate an approximate incidence rate of 1--2 new cases/100,000 inhabitants per year. This represents about 0.5% of all malignancies. Some articles indicate that, although rare, NETs are presenting a discreet and progressive rise in their incidence \[[@B4]\].

The gastrointestinal tract is the most common primary site (62%), where appendix (27%) and the small intestine (15%) are the most prevailing, followed by the lungs (23%). It is relevant to highlight that up to 12% of the patients present metastases from an unknown primary site \[[@B4]\].

Within the spectrum of NETs, on the one side, well-differentiated NETs can be found (formerly called carcinoid tumors), usually with a painless clinical course, besides being curable by simple resection when viable. On the other side of the spectrum, there are poorly differentiated neuroendocrine carcinomas (NECs), of a more aggressive clinical course, producing metastases with greater frequency and, usually, requiring isolated or adjuvant chemotherapy \[[@B1], [@B2]\]. Cutaneous manifestations from NETs are not uncommon, especially those exhibiting carcinoid syndrome. Flushing is the most common manifestation, present in all secretory tumors. Cutaneous metastases, however, are rare \[[@B3], [@B5]\].

We present the case of a patient with a diagnosis of NEC of undetermined primary site, diagnosed with lymph node metastasis and cutaneous lesions.

Case Report {#sec1_2}
===========

A 65-year-old man with arterial hypertension was diagnosed 2 years before with NEC based on histopathological examination of a swollen lymph node in the right inguinal region. The patient was scanned with CT and scintigraphy; however, the site of the neoplasia was not identified. Nevertheless, 6 months ago, chemotherapy treatment was initiated with a combined scheme of carboplatin and etoposide.

Three months ago the patient noted nodular lesions visible on the right lower limb with progressive growth that led to the request of a consultation by a dermatologic peer.

At clinical examination, the lesions were more palpable than visible. There was no overlying erythema. They were restricted to the right thigh, in a linear trajectory, and the right buttock (fig. [1](#F1){ref-type="fig"}, fig. [2](#F2){ref-type="fig"}, fig. [3](#F3){ref-type="fig"}). The lesions were painless at touch, had a hardened consistency, measured up to 1.5 cm and were not adhered to deeper planes.

An excisional biopsy of one of the skin lesions was performed. Histopathological examination showed a nodule occupying the medium/deep reticular dermis and hypodermis, with expansive growth, comprising monomorphic cells with poorly defined cytoplasmic borders, round nucleus, and fine granular chromatin, delimited by delicate septa of connective tissue (fig. [4](#F4){ref-type="fig"}, fig. [5](#F5){ref-type="fig"}). Numerous figures of mitoses were noted. Immunohistochemistry showed focal positivity in paranuclear dot for CK20 (fig. [6](#F6){ref-type="fig"}), positivity for chromogranin (fig. [7](#F7){ref-type="fig"}) and synaptophysin and a cell proliferation index evaluated by Ki67 of about 60% (fig. [8](#F8){ref-type="fig"}). These findings were interpreted as compatible with cutaneous NEC metastasis.

The case was considered by the clinical oncologist as loss of response to treatment and progression of disease. Therefore, a chemotherapy rescue scheme was initiated with irinotecan. The patient is being followed up by both specialties.

Discussion {#sec1_3}
==========

Carcinomas with unknown primary site represent about 2.3--4.2% of all malignant neoplasia cases (being seventh or eighth in frequency, depending on the casuistry). They seem to affect men more frequently, with onset in the fifth or sixth decade of life, being the fourth cause of death in both genders. Of these, 50% are at least moderately differentiated adenocarcinomas. Up to 30% are poorly differentiated, and the NETs of unknown primary site are included in this group \[[@B6]\].

The detection of the primary site in metastatic NET is a challenge. The approach includes endoscopy and imaging (tomography and scintigraphy). Recently, evidences indicate benefits by using endoscopic ultrasound and PET CT \[[@B7]\].

As a group, NETs produce metastases in 30% of cases, and among these a greater portion is attributed to NEC. The metastatic disease signals a worse prognosis. Other worse prognostic factors identified at histopathological examination are vascular and lymphatic invasion, a high grade of cell atypia, an increased nucleus/cytoplasm ratio, the presence and extension of necrosis, besides an increased mitotic index \[[@B2], [@B8]\]. The cell proliferation index analyzed by immunohistochemistry (Ki67) contributes to this assessment. Poorly differentiated NEC, with a Ki67 \>20%, are associated with worse prognosis \[[@B2]\].

The most common metastatic sites of NETs are the lymph nodes, liver and lung. Cutaneous metastases are considered rare. Only 28 articles were accessed, totaling 31 cases, which are summarized in table [1](#T1){ref-type="table"}. There was a slight prevalence in men (16/31), with a mean age of 55 years at the time of diagnosis (ranging from 19 to 82 years). In most cases, the lesions were single or multiple nodules, nonulcerated, painless, of slow growth, ranging from 0.5 to 2.5 cm in diameter and clinically unspecific like other cutaneous metastasis. The location was most frequently on the cephalic segment (typically on the scalp) and/or trunk. We call attention to two distinct cases: (1) painful spots referred by the patient without visible or palpable cutaneous lesions; (2) single hardened lesion on the eyelid, simulating the primary cutaneous lesion \[[@B8], [@B9], [@B10], [@B11], [@B12], [@B13], [@B14], [@B15], [@B16], [@B17], [@B18], [@B19], [@B20], [@B21], [@B22], [@B23], [@B24], [@B25], [@B26], [@B27], [@B28], [@B29], [@B30], [@B31], [@B32], [@B33], [@B34], [@B35]\].

Most of the cases presented with painless lesions, although in some patients the lesions can be painful. In this context, primary painful cutaneous tumors are important differential diagnoses. They can be easily remembered by the acronym LEND AN EGG (leiomyoma, eccrine spiradenoma, neuroma, dermatofibroma, angiolipoma, neurilemmoma, endometrioma, glomus tumor and granular cell tumor) \[[@B36]\].

Prognosis is not good. The 5-year survival rate is 19% for patients with metastatic NEC \[[@B3]\]. Despite chemotherapy, an effort should be made for the identification of the primary site, since its resection will increase the disease-free survival and allow appropriate chemotherapy \[[@B7]\].

Conclusion {#sec1_4}
==========

Cutaneous metastases of NEC are rare, but it is important to emphasize the relevance of the dermatologist in such cases. Clinical suspicion and histopathology diagnosis permitted the identification of the disease progression, which was a determinant factor for modifying the chemotherapy protocol.
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###### 

Cases of cutaneous metastasis of NEC found in PubMed

  ------------------------------ ------------ -------- ------------------------ ------------------------------------------------------------------------------------
  First authors \[Ref.\], year   Age, years   Gender   Primary site             Lesion type and location
                                                                                
  Reingold \[[@B9]\], 1960       35           M        Lung                     Subcutaneous nodules; diffusely distributed, except face, hands and feet
                                                                                
  Bean \[[@B10]\], 1968          62           M        Unknown                  Multiple nodules in a dome format; scalp and anterior trunk
                                                                                
  Colin-Jones \[[@B11]\], 1969   73           F        Pancreas                 Painless nodules; abdomen and limbs
                                                                                
  Sullivan \[[@B12]\], 1981      19           M        Testicles                Nodules; trunk
                                                                                
  Archer \[[@B13]\], 1985        68           F        Lung                     Subcutaneous nodules, cervical region; trunk and thighs
                                                                                
  Rodriguez \[[@B14]\], 1992     80           M        Stomach                  Subcutaneous nodules; forehead, posterior cervical region, trunk and thighs
                                                                                
  Schmidt \[[@B15]\], 1994       63           F        Larynx                   Painful nodules, diffusely distributed on the body
                                                                                
  Grunewald \[[@B16]\], 1996     62           F        Gastrointestinal tract   Nodule; umbilical scar
                                                                                
  McCracken \[[@B17]\], 1996     67           M        Gastrointestinal tract   Hard nodule; left superior eyelid
                                                                                
  Ereño \[[@B18]\], 1997         72           F        Larynx                   Hard nodules; scalp
                                                                                
  De Argila \[[@B19]\], 1999     71           M        Lung                     Single pinkish erythematous nodule with superficial erosion; face
                                                                                
  Ottinetti \[[@B20]\], 2003     61           M        Larynx                   Hard erythematous violaceous nonulcerated nodules; trunk
                                                                                
  Zhang \[[@B21]\], 2003         34           F        Pancreas                 Hard nodule; periumbilical
                                                                                
  Bell \[[@B22]\], 2005          69           M        Rectum                   Multiple subcutaneous nodules
                                                                                
  Vidulich \[[@B23]\], 2007      76           F        Breast                   Nodules in annular disposition, in contiguity to a breast tumoral mass
                                                                                
  Santi \[[@B24]\], 2008         60           M        Lung                     Erythematous violaceous nodule, with rapid growth; dorsum
                                                                                
  Chung \[[@B25]\], 2008         31           F        Uterus                   Two erythematous purpuric nodules; scalp
                                                                                
  Lee \[[@B26]\], 2009           20           M        Bladder                  Single erythematous dome format nodule with central ulceration; scalp
                                                                                
  Simpson \[[@B27]\], 2009       82           M        Larynx                   Painful erythematous papules and nodules; head, neck and trunk
                                                                                
  Blochin \[[@B28]\], 2010       55           F        Lung                     Painful points, without visible erythema or palpable nodule; scalp
                                                                                
  Yu \[[@B29]\], 2010            50           F        Lung                     Single subcutaneous nodule; right axilla
                                                                                
  Sanii \[[@B30]\], 2011         79           F        Thyroid                  Multiple erythematous painful nodules and plaques; right forearm, abdomen and back
                                                                                
  Boyd \[[@B31]\], 2012          50           F        Breast                   Erythematous papules and nodules over the skin of the reconstructed left breast
                                                                                
  Fluehler \[[@B32]\], 2013      65           M        Gastrointestinal tract   Single erythematous nodular lesion with telangiectasias; face
                                                                                
  Yuan \[[@B33]\], 2014          60           F        Lung                     Single erythematous nodular lesion on the breast
                                                                                
  Ishida \[[@B34]\], 2014        55           M        Lung                     Single subcutaneous nodule; scalp
                                                                                
  Wang \[[@B35]\], 2014          62           M        Gastrointestinal tract   Multiple subcutaneous nodules; scalp
                                                                                
  Jedrych \[[@B8]\], 2014        50           F        Lung                     Single painless nodule, nonulcerated, slow progressive growth; scalp
                                                                                
                                 74           M        Lung                     Single painless nodule, nonulcerated, slow progressive growth; scalp
                                                                                
                                 67           F        Pancreas                 Single painless nodule, nonulcerated, slow progressive growth; scalp
                                                                                
                                 67           F        Gastrointestinal tract   Single painless nodule, nonulcerated, slow progressive growth; dorsum
  ------------------------------ ------------ -------- ------------------------ ------------------------------------------------------------------------------------
